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Accumulation of T regulatory (Treg) cells within the central nervous system (CNS) dur-
ing experimental autoimmune encephalomyelitis (EAE) is essential for the resolution of
disease. CNS Treg cells have been shown to uniformly express the Th1-associated mole-
cules,T-bet and CXCR3. Here, we report that the expression ofT-bet is not required for the
function of these Treg within the CNS. Using mice that lacked T-bet expression specifically
within theTreg compartment, we demonstrate that there was no deficit inTreg recruitment
into the CNS during EAE and no difference in the resolution of disease compared to control
mice. T-bet deficiency did not impact on the in vitro suppressive capacity of Treg. Transfer
of T-bet-deficient Treg was able to suppress clinical signs of either EAE or colitis. These
observations demonstrate that, although Treg can acquire characteristics associated with
pathogenic T effector cells, this process is not necessarily required for their suppressive
capacity and the resolution of autoimmune inflammation.
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INTRODUCTION
The ability of Foxp3+ T regulatory (Treg) cells to acquire proto-
typic T effector (Teff) cell characteristics has been reported to aid
their migration to sites of inflammation and increase their capacity
to suppress distinct types of inflammatory response. The expres-
sion of IRF4 has been implicated in the control of Th2 responses
(1). Induction of STAT3 signaling in Treg, resulting in expres-
sion of RORγt and CCR6, has been identified as a requirement
for Treg to suppress Th17 responses (2). Furthermore, CCR6-
deficient Treg were inhibited in their ability to migrate to sites of
inflammation containing Th17 cells (3–5). Similarly, during Th1-
dominated responses, Treg have been shown to acquire expression
of the Th1 markers T-bet and CXCR3 (6–8), and CXCR3-deficient
Treg are thought to have a reduced capacity for trafficking to sites of
Th1 inflammation (9, 10). Indeed, CXCR3-transfected Treg were
found to accumulate at sites of inflammation more efficiently than
non-transfected Treg in a murine graft versus host model (11). T-
bet-deficient Treg have also proved inferior compared to wild-type
(WT) Treg at suppressing Th1-led multi-organ autoimmunity in
scurfy mice (7).
Using experimental autoimmune encephalomyelitis (EAE) as a
model of central nervous system (CNS) autoimmune inflamma-
tion, we have previously shown that Treg cells accumulate within
the CNS during EAE and are essential for resolution of disease
(12, 13). Although EAE pathology is considered to be mediated
by a heterogeneous mix of Teff cell populations, namely Th1 and
Th17 cells (14, 15), the Treg cells that accumulate within the CNS
during EAE uniformly express the Th1-associated transcription
factor T-bet and the homing molecule CXCR3 (16). In addition
to this observation, it has previously been reported that EAE in
CXCR3-deficient mice results in a more severe or protracted dis-
ease course and reduced accumulation of Treg within the CNS (17,
18). These findings implied that the acquisition of Th1 character-
istics by Treg cells might be required for their suppression of CNS
inflammation during EAE. Here, we tested this possibility by the
generation of mice that lacked the ability to express T-bet specif-
ically in the Treg compartment. We found no evidence that these
mice had impaired Treg cell accumulation in the CNS or natural
recovery from EAE. Furthermore, therapeutically administered T-
bet-deficient Treg cells were able to prevent the development of
either EAE or colitis.
MATERIALS AND METHODS
MICE, ANTIGENS, AND TISSUE CULTURE MEDIUM
Wild-type C57BL/6 (CD45.2/CD90.2 or CD45.2/CD90.1),
B10.PLxC57BL/6 (CD45.2/CD90.2), and Tbx21-/- (KO; obtained
from The Jackson Laboratory) were used. Tg4 mice (CD90.1)
express a transgenic TCR recognizing the Ac1-9 peptide of myelin
basic protein (MBP) (19). Foxp3tm4(YFP/cre)Ayr mice (20) were
kindly provided by Dr. A. Rudensky. T-betfl/fl (21) (kindly pro-
vided by Dr. S. Reiner) were crossed with Foxp3tm4(YFP/cre)Ayr
mice to generate T-betfl/flFoxp3-Cre conditional KO (cKO) mice
and T-betfl/WTFoxp3-Cre conditional heterozygous (cHet) mice
(both CD90.2). These lines expressed YFP under control
of the Foxp3 promoter. Tbx21-/- mice were crossed with
Tg4xFoxp3.LuciDTR-4 (CD45.1) (Tg4.WT) (22) to generate
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Tbx21-/-Tg4xFoxp3.LuciDTR-4 (CD45.1) (Tg4.T-bet-/-) mice.
Both the Tg4.WT and Tg4.T-bet-/- lines expressed GFP under
control of the Foxp3 promoter. All mice were bred under spe-
cific pathogen-free conditions at the University of Edinburgh.
All experiments were approved by the University of Edinburgh
Ethical Review Committee and were performed in accordance
with UK legislation. The myelin oligodendrocyte glycoprotein
35–55 peptide (pMOG) and the MBP Ac1–9 and Ac1–9 (4Tyr)
peptides were obtained from Cambridge Research Biochemicals
(Cleveland, UK). Tissue culture medium (RPMI 1640 medium)
was supplemented with 2 mM l-glutamine, 100 U/ml penicillin,
100µg/ml streptomycin, and 5× 10-5 M 2-ME (all from Invitro-
gen Life Technologies, Paisley, UK) plus 10% FCS (Sigma, Poole,
UK). Cells isolated from immunized mice were cultured in X-
VIVO15TM serum-free medium (Lonza, Walkersville, MD, USA)
supplemented with 2 mM l-glutamine and 5× 10-5 M 2-ME.
CELL PURIFICATION AND CULTURE
CD4+ T cells were purified by magnetic cell sorting (Miltenyi
Biotec, Germany) prior to surface staining and sorting by FACS.
CD4+CD62LhiCD25+GFP+ nTreg were isolated from Tg4.WT or
Tg4.T-bet-/- mice. CD4+CD62LhiCD25-GFP- naïve T cells from
Tg4.WT mice were used as T responder cells for in vitro suppres-
sion assays, for donor cells in MBP-induced EAE, and as starting
populations for induced Treg (iTreg) generation as previously
described (22). Naïve populations from non-Tg4 mice were also
used for iTreg generation, with stimulation provided by anti-CD3
(clone 145.2C11; eBioscience, Hatfield, UK) plus anti-CD28 (clone
37.51; eBioscience). For Th1 polarization, naïve T cells were cul-
tured for 72 h on anti-CD3 plus anti-CD28 coated 24-well plates
at a density of 0.25× 106/well in the presence of 10 U/ml rIL-
2, 25 ng/ml rIL-12, and 25 ng/ml rIL-18 (all RnD Systems). After
48 h, cells were split and the concentration of IL-2 was raised to
20 U/ml. For suppression assays, Th1 cells were generated from
Tg4 splenocytes with 10µg/ml Ac1-9 in the presence of IL-12,
IL-18, and IL-2 as described above. At the end of culture, cells
were rested in 20 U/ml IL-2 for 48 h before use in the suppression
assay.
INDUCTION OF EAE
For MOG-induced EAE, C57BL/6, cKO, or cHet mice were immu-
nized s.c. with 100µg pMOG emulsified in CFA containing 200µg
heat-killed Mycobacterium tuberculosis H37RA (Sigma-Aldrich,
Poole, UK). For MBP-induced EAE, C57BL/6xB10.PL host mice
first received an i.v. injection of 1× 106 naïve Tg4 CD4+ T cells
(with or without an equal number of Tg4 iTreg) 1 day before
immunization with 10µg Ac1–9 (4Tyr) in CFA. Mice also received
200 ng of pertussis toxin (Health Protection Agency, Dorset, UK)
in 0.5 ml PBS i.p on the day of immunization and again 2 days
later. Passive EAE was induced with MOG-responsive T cells using
a previously described protocol (15). Clinical signs of EAE were
assessed using the following scoring index: 0, no signs; 1, flac-
cid tail; 2, impaired righting reflex and/or gait; 3, partial hind
limb paralysis; 4, total hind limb paralysis; 5, hind limb paralysis
with partial front limb paralysis; 6, moribund or dead. Assessment
of CNS (brain and spinal cord) immune cells was conducted as
described previously (13).
Tg4 IN VIVO SUPPRESSION ASSAY
C57BL/6xB10.PL mice were immunized with MBP peptide as
described above for EAE induction 1 day after transfer of 1× 106
naïve Tg4 (CD90.1) responder cells with or without 1× 106
Tg4.WT or Tg4.T-bet-/- iTreg. Seven days after immunization,
spleens and draining lymph nodes (dLN) were isolated for assess-
ment of responder cell accumulation, cell cycle status, and IFN-γ
production by FACS as described below.
T-CELL TRANSFER MODEL OF COLITIS
RAG1-/- mice were injected i.v. with PBS or 5× 105 naïve WT
CD4+ T cells (CD4+CD62LhiYFP-) from Foxp3tm4(YFP/cre)Ayr
mice in the presence or absence of 1.5× 105 KO nTreg
(CD4+CD62LhiYFP+) from T-bet cKO mice. Mice were moni-
tored daily and weighed three times a week until cull at 6 weeks
after transfer. Colons were weighed and lymphoid cells isolated
from the lamina propria. Briefly, the intestinal epithelial layer
was removed by incubation in HBSS 2 mM EDTA for 30 min,
and the remaining tissue digested with 1.25 mg/ml collagenase-4
(Worthington) and 30µg/ml DNase-1 (Roche) in culture medium
and disaggregated with a gentle MACS dissociator (Miltenyi).
Retrieved lymphoid cells were stained and analyzed by flow
cytometry.
IN VITRO SUPPRESSION AND RECALL CYTOKINE PRODUCTION ASSAYS
Suppression assays were performed by culturing naïve or Th1 Tg4
responder cells (1–2× 104/well) for 9 6h with increasing numbers
of Tg4 iTreg or nTreg in the presence of 1× 105 irradiated (30 Gy)
splenic C57BL/6xB10.PL APC and 10µM MBP Ac1-9 peptide.
0.5µCi [3H] thymidine (Amersham Biosciences, Amersham, UK)
was added for the final 16 h and incorporation measured by β-
scintillation counting (Wallac, Turku, Finland). For assays using
Th1 responder cells, IFN-γ production was measured by ELISA.
For assessment of recall cytokine production from immunized or
EAE mice, lymphoid cells (splenocytes or dLN) were cultured in
96-well flat-bottom plates (BD) at 6× 105 dLN cells/well, 6× 105
CNS mononuclear cells/well, or 8× 105 splenocytes/well. Cells
were stimulated with 20µg/ml pMOG or 20µg/ml MBP Ac1-9
for 24 h and cytokine production was measured by intracellular
cytokine staining.
ANTIBODIES AND FACS ANALYSIS
Cells were stained with the following antibodies and iso-
type controls (all from eBioscience, except where stated).
Anti-CD4-eFluor450, anti-CD4-BV650 (BioLegend, San Diego,
CA, USA), anti-CD90.1-APC, anti-CD45.1-FITC, anti-FoxP3-
efluor450, anti-T-bet-PerCPCy5.5, anti-CXCR3-AF647, anti-
CD25-APC, anti-CD62L-PE, anti-IFNγ-eFluor450, anti-GM-
CSF-PE (BD),anti-IL-17-PerCPCy5.5,anti-CD11b-AF700 (BioLe-
gend), anti-Ki-67-(PE/PerCPCy5.5), Rat IgG1 (PE, efluor450,
PerCPCy5.5), Rat IgG2a (APC, efluor450, PerCPCy5.5, PE), mouse
IgG1-AF647, and Armenian hamster IgG-APC. A fixable viability
marker AF780 or eFluor455 (eBioscience) was also used. Flow
cytometric data were acquired using a BD LSR Fortessa cell ana-
lyzer (BD) and data analyzed using FlowJo software (Treestar
version 3.2.1, Ashland, OR, USA). Cell sorting used an ARIA II
cell sorter (BD Biosciences). For intracellular cytokine staining
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in response to peptide, brefeldin A (eBioscience, 1000x stock)
was added for the last 4 h of culture. Samples for transcription
factor staining and samples for intracellular cytokine staining were
washed once in FACS buffer (PBS, 2% FCS, 0.01% NaN3) and sur-
face stained prior to processing for intracellular staining using
proprietary buffers according to the manufacturer’s instructions
(eBioscience for transcription factor staining or BD Pharmingen
for cytokine staining). After incubation in fix/perm buffers, cells
were stained for intracellular antigens.
STATISTICS
Statistical analysis of results was performed using the Mann-
Whitney U test or the Kruskal-Wallis with Dunn’s post hoc
test.
RESULTS
Tbx21fl/ flFoxp3-CRE CONDITIONAL KO MICE RETAIN NORMAL
EFFECTOR T-CELL FUNCTION
To test if T-bet is required by Treg to inhibit EAE pathology
driven by T-bet sufficient T cells, we generated Tbx21fl/flFoxp3-
Cre cKO mice that specifically lacked T-bet expression only in
the Foxp3-expressing Treg compartment (Figure 1A). As T-bet
enables CXCR3 expression by Treg (7), Treg from these mice also
showed abolished capacity for CXCR3 expression (Figure 1B). No
differences were observed in T-bet or CXCR3 expression between
the control T-bet cHet WT mice. Importantly, CD4+Foxp3- cells
from cKO mice expressed similar levels of T-bet and CXCR3 as
those from WT and cHet mice (Figures 1A,B), indicating no
impairment of T-bet expression within the Teff population.
We have previously reported that generation of Foxp3+ iTreg
cells from naïve CD4+ T cells results in T-bet expression (22).
To test whether cells from cKO mice lose the ability to express
T-bet and CXCR3 upon induction of Foxp3 expression, we gen-
erated iTreg from naïve CD4+ T cells isolated from cKO and
control mice. At the end of culture, >95% of the cells in all
groups were expressing Foxp3 (Figure 1C), whereas T-bet and
CXCR3 expression was only evident in the cells from WT and
cHet mice (Figures 1D,E). Neither iTreg generated from T-bet KO
mice nor cKO mice expressed T-bet or CXCR3, demonstrating
the ability to express T-bet is lost upon Foxp3 expression in cKO
mice.
In order to verify that Teff cells from cKO mice did not lack
the ability to express T-bet, naïve CD4+ T cells were isolated and
cultured under Th1 polarizing conditions. In contrast to Th1 cells
generated from global T-bet KO mice, Th1 cells generated from
cKO mice expressed IFN-γ, T-bet, and CXCR3 at levels similar to
those seen in similar Th1 cells from either WT and control cHet
mice (Figures 1F–H). The inability to express T-bet in cKO mice
was therefore confined to CD4+Foxp3+ cells.
Treg EXPRESSION OF T-bet IS REDUNDANT FOR THE RESOLUTION
OF EAE
Following induction of EAE by active immunization with pMOG,
there was no difference in the severity or resolution of disease
between cKO and cHet control mice (Figure 2A). Accordingly,
no differences were observed in the proportion (Figure 2B) or
number (data not shown) of Foxp3+ cells recruited into the CNS
FIGURE 1 | Characterization of CD4+ T cells fromT-bet cKO mice.
(Continued )
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FIGURE 1 | Continued
Representative plots of (A)T-bet vs. Foxp3 and (B) CXCR3 vs. Foxp3
staining within the CD4+ splenocyte population of unmanipulated C57BL/6
(WT), Tbx21-/- (KO), T-bet cKO, and T-bet cHet mice. Naïve CD4+ T cells were
isolated from WT, KO, cKO, and cHet mice and cultured under iTreg
generating (C–E) or Th1 polarizing (F–H) conditions. Representative plots of
(C) Foxp3, (D)T-bet, and (E) CXCR3 staining within the CD4+ population
following iTreg generation. (F) IFN-γ, (G)T-bet, and (H) CXCR3 staining
within the CD4+ population of Th1 polarized cells. Data are representative
of three experiments giving consistent results (n=4 mice per group).
during disease (Figures 2B,C), suggesting no deficit in the ability
of Treg to migrate into the CNS of cKO mice. In line with our
previous report (16), T-bet was expressed by Treg within the CNS
and not the periphery of cHet mice (Figures 2D,E), verifying
that this phenotype is enriched at the site of inflammation in
mice where T-bet expression is unrestricted. Despite the lack of
T-bet expression in the CD4+Foxp3+ population of the cKO mice
(Figures 2D,E), there was also no difference in the proportion
of CD4+ cells producing pro-inflammatory cytokines, including
IFN-γ, within the CNS (Figure 2F). Of note, no differences were
observed in the proportion of T cells staining for GM-CSF, the
only T-cell-derived pro-inflammatory cytokine that is believed to
be critical for EAE pathogenesis (23, 24). Although IFN-γ pro-
ducing CD4+ T cells are evident within the CNS of this model,
the induction of EAE through immunization with myelin-derived
peptides results in a heterogeneous pathogenic T-cell population
including both Th1 and Th17 cells (14, 15); indeed, IL-17 pro-
ducing CD4+ T cells were evident in the CNS (Figure 2F). To
better scrutinize the requirement of T-bet expression in Treg for
the control of Th1 responses during EAE, disease was induced
via transfer of IL-12-conditioned antigen-experienced WT T cells
into cKO or cHet control mice. Similarly to active EAE, the dis-
ease course was no different between cKO and control cHet mice
(Figure 2G) and no disparity was observed in the resolution
of clinical signs (Figure 2H) demonstrating that Treg do not
require T-bet expression for the resolution of Th1-driven CNS
inflammation.
T-bet-DEFICIENT Treg CAN SUPPRESS Th1 RESPONSES BOTH IN VITRO
AND IN VIVO
As a lack of T-bet expression did not appear to inhibit the res-
olution of active EAE or passive EAE using IL-12-conditioned
T cells, the ability of T-bet-deficient Treg to suppress the pro-
liferation of naïve CD4+ T cells was tested. These experi-
ments used MBP-responsive Treg derived from the previously
described Tg4xFoxp3.LuciDTR-4 mice (22) (here referred to
as Tg4.WT) and compared their function with Treg from
Tbx21-/-Tg4xFoxp3.LuciDTR-4 mice (Tg4.T-bet-/-). T cells from
both of these strains express a transgenic TCR specific for the MBP
(Ac1-9) peptide and eGFP under the Foxp3 promoter, enabling
high purity Foxp3+ nTreg and Foxp3- naïve T-cell populations
to be isolated by FACS. In vitro assays testing the ability of these
two Treg populations to inhibit the proliferation of naïve CD4+
Tg4.WT responder T cells showed that their suppressive abili-
ties were equivalent. This was the case using either freshly iso-
lated nTreg or in vitro generated iTreg (Figures 3A,B). The same
was observed for polyclonal T-bet-deficient nTreg and iTreg and
polyclonal naïve T cells following stimulation with anti-CD3 (data
not shown).
To test suppressive function in vivo, we used a previously
described system in which naïve CD90.1-expressing Tg4 respon-
der cells, with or without a corresponding cohort of CD45.1-
expressing Tg4 iTreg, were transferred into B10.PLxC57BL/6 host
mice (expressing CD45.2 and CD90.2) prior to immunization with
MBP peptide in CFA (22). Tg4.T-bet-/- iTreg were able to fully
inhibit the resulting development of EAE (Figure 3C). Consistent
with this, accumulation of Tg4 responder cells in the spleen and
dLN was significantly reduced by co-transfer of either Tg4.WT or
Tg4.T-bet-/- iTreg cells (Figure 3D). Similar results were obtained
when using nTreg cells (data not shown). In accordance with this,
the numbers of responder Tg4 cells in cell cycle (as determined
by ex vivo Ki-67 staining) and staining for IFN-γ after in vitro
restimulation with MBP peptide were decreased in the spleen and
dLN of mice that had received either WT or T-bet-/- iTreg cells
(Figures 3E,F).
To test the ability of T-bet-/- Treg to suppress pre-activated Th1
cells, an in vitro suppression assay was conducted using Tg4 Th1
cells as responder cells. Tg4.WT and Tg4.T-bet-/- iTreg suppressed
production of IFN-γ by the responder Th1 cells with equivalent
efficacy as determined by iTreg cell dilution (Figure 3G). From
these data, we conclude that T-bet-/- Treg are effective at both
preventing and inhibiting antigen-driven Th1 responses.
T-bet-DEFICIENT Treg CAN SUPPRESS COLITIS
In order to determine if T-bet is required by Treg to suppress
another model of T-cell-driven inflammation, a T-cell transfer
model of colitis similar to those previously described (25) was
used in which pathogenesis can be prevented by co-transfer of Treg
cells. Transfer of naïve WT T cells alone into RAG1-/- host mice
led to a loss in total body weight and an increase in colonic weight
(Figures 4A,B). Co-transfer of Treg isolated from T-bet cKO mice
allowed maintained body weight and prevented changes to colon
weight. Furthermore, CD4+Foxp3+ cells were present and num-
bers of CD4+ Foxp3- cells were significantly reduced within the
lamina propria of mice that received T-bet cKO Treg compared to
those that received naïve T cells alone (Figure 4C). We conclude
that Treg do not require T-bet expression to suppress the T-cell
transfer model of colitis.
DISCUSSION
Unaltered Treg infiltration of the CNS and EAE resolution in cKO
mice suggests that, in this disease setting, expression of T-bet and
CXCR3 by CNS-targeting Treg may be an epiphenomenal conse-
quence of exposure to the local inflammatory milieu rather than
a necessity for their function.
Previous studies have implicated T-bet and CXCR3 as impor-
tant factors in the suppression of Th1 responses by Treg, either by
endowing Treg with superior homeostatic properties or by facili-
tating their migration to, and accumulation at, sites of Th1 inflam-
mation (7, 10, 18). However, several other studies have reported
that T-bet-deficient Treg are equally suppressive as WT Treg in vitro
(26, 27), and in certain Th1-mediated diseases can even have
greater suppressive capacities than WT Treg (28). Together, these
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FIGURE 2 |Treg cells do not requireT-bet for the resolution of EAE. EAE
was induced in T-bet cKO and T-bet cHet mice by immunization with pMOG.
(A) Mean clinical scores±SEM. Incidence in both groups was 100%.
(B,C) CD4+ cells expressing Foxp3 within the CNS and spleen at day 13 of
disease. (D,E)T-bet staining (MFI) within the CD4+Foxp3- and CD4+Foxp3+
populations of the CNS and spleen (E) (dotted line represents MFI of
isotype control staining), (F) GM-CSF, IFN-γ, IL-17, and TNF-α production
following overnight culture of CNS mononuclear cells with pMOG (gated on
CD4+CD11b- T cells). Data are from one of three experiments giving
consistent results, n=8 mice per group. (G) Mean clinical EAE
scores±SEM of cKO or cHet mice that received passive transfer of 3×106
WT IL-12-conditioned pMOG-reactive cells. Data are from one of two
experiments giving consistent results, n=8 mice per group. Maximum EAE
score for each mouse was 0, 0, 0, 0, 3, 3, 3, 3 (cHet) and 0, 0, 2, 2, 3, 3, 3, 3
(cKO). (H) Mean EAE score±SEM from day of onset of those mice that
developed disease after passive transfer.
reports imply that T-bet-deficient Treg may have some decreased
ability to traffic to sites of Th1-mediated inflammation but have
no defect in their suppressive modalities.
The requirement for CXCR3 expression by Treg cells (and
indeed Teff cells) to allow their migration into the CNS during EAE
is of some debate. It has been reported that blockade of CXCR3
can inhibit leukocyte migration into the CNS and the induction of
passive EAE, but has no effect in the active EAE model (29). Inhibi-
tion of the CXCR3 ligand CXCL10 has also been reported to inhibit
disease induction and T-cell migration (30, 31). However, other
studies have shown increased disease severity in CXCR3-deficient
mice, with one report detecting no difference in overall leukocyte
migration (17), and another demonstrating reduced accumula-
tion of Treg within the CNS (18). Despite these observations, the
exact role of CXCR3 expression on Treg cells during EAE has not
previously been investigated. Through the use of global T-bet KO
mice, we have previously observed that T-bet, and hence CXCR3,
is not required for the induction of EAE, nor for the resolution
of disease in this model (32). Furthermore, we have not observed
differences the recruitment of Treg into the CNS during EAE in
T-bet KO mice compared to WT mice (data not shown). How-
ever, the dominant cytokine produced by CD4+ Teff cells in the
CNS of T-bet KO mice is IL-17 (32), rather than IFN-γ as seen in
WT mice. This may indicate that, rather than T-bet and CXCR3
expression, Treg would require a Th17-like phenotype in order to
resolve EAE in this model. Through the use of T-bet cKO mice, we
have demonstrated that, despite a normal CNS Teff cell compart-
ment dominated by IFN-γ+ cells, T-bet-deficient Treg remain able
to migrate to the site of inflammation and coordinate disease res-
olution. Therefore, specialization may not be universally required
for Treg migratory potential or function.
Few studies have investigated the ability of T-bet-deficient Treg
to specifically suppress Th1 responses. Koch et al. demonstrated
that T-bet-deficient Treg were unable to protect scurfy mice from
spontaneous autoimmune inflammation and subsequent death
(7). Similarly to EAE, the inflammation observed in scurfy mice
is heterogeneous in nature where both Th1 and Th17 cells can be
detected (7, 33), although Th1 responses are thought to dominate
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FIGURE 3 |T-bet is not required forTreg cell suppressive function. Varied
numbers of Tg4.WT or Tg4.T-bet-/- nTreg (A) or iTreg (B) were co-cultured with
a fixed number of naïve Tg4 responder cells and stimulated with MBP Ac1-9
(as described in Section “Materials and Methods”). Data are from one of two
experiments giving consistent results. (C–F) C57BL/6xB10.PL were
immunized with MBP Ac1-9 1 day after transfer of 1×106 naïve CD4+ Tg4
responder cells (CD90.1), with or without 1×106 Tg4.WT or Tg4.T-bet-/- iTreg
(CD45.1) for development of EAE (C) (mean clinical scores±SEM), or for ex
vivo analysis of spleen and dLN after 7 days (D–F). Ex vivo numbers of
Tg4.CD90.1 responder cells (D), Ki-67+ responder cells (E). IFN-γ+ responder
cells after overnight culture with MBP peptide (F). Data are from one of three
experiments giving consistent results, n=5 mice per group. (G) IFN-γ
production by Tg4 Th1 responder cells co-cultured with Tg4.WT or Tg4.T-bet-/-
iTreg cells. Data are from one of two experiments giving consistent results.
both models. In accordance with this, Treg cells transferred into
scurfy mice up-regulate expression of T-bet and CXCR3, as we see
in the CNS of EAE mice. Despite these similarities, T-bet appears
necessary for Treg to control the Th1 response in multi-organ
inflammation observed in scurfy mice but not CNS inflammation
during EAE. This might be accounted for by different requirements
for migration to distinct sites of inflammation, or by variation in
the inflammatory milieu between models. However, disease can
occur in either model in the absence of IFN-γ or T-bet (and
therefore CXCR3) (32–35) indicating other pathological roles for
inflammatory T cell other than Th1 cells. Indeed, the study by Koch
et al. did not report on survival rates between scurfy mice that did
not receive Treg compared to those that received T-bet-deficient
Treg, leaving open the possibility that T-bet-deficient Treg did have
a partially beneficial role in that model.
We also used a passive transfer EAE model (transferring IL-12-
conditioned Teff cells). It is important to note that T-bet KO Teff
cells cannot transfer EAE in this model (32). However, we demon-
strate here that host Treg cells do not require T-bet to resolve
this T-bet-dependent pathology. The lack of requirement for T-
bet expression for Treg function was not a feature restricted to
CNS inflammation, as it was replicated in a colitis model also
reported to require Th1 responses (28, 36). Consistent with this,
we demonstrated that T-bet-deficient Treg were capable of sup-
pressing antigen-driven Th1 function (IFN-γ production) both
in vitro and in vivo.
In summary, T-bet is not required by Treg cells for their sup-
pression of Th1 responses, or for their migration into the CNS to
coordinate the resolution of EAE. Despite the phenotypic changes
seen in WT Treg cells during EAE (gain of T-bet and CXCR3
expression), these characteristics appear to play no role in their
function. These results suggest that the manipulation of Treg cells
to drive T-bet and CXCR3 expression would not endow them with
a therapeutic advantage.
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FIGURE 4 |Treg cells do not requireT-bet to suppressT-cell-driven
colitis. RAG1-/- mice received PBS, 5×105 naïve WT CD4+CD62LhiYFP-
T cells alone, or in combination with 1.5×105 T-bet cKO CD4+CD62LhiYFP+
T cells i.v. and were monitored for weight loss for 6 weeks. (A) Mean body
weight change±SEM. At the end of the experiment, by colon weight was
measured (B) and numbers of CD4+Foxp3- T cells present in the lamina
propria were determined by flow cytometry (C). Data are from one of two
experiments giving consistent results (n=4–5 mice per group).
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